Leserbrief
Semaglutide reduces the absolute risk of major cardiovascular events by 1.5%
BMJ · 15.01.2024 · q53
DOI: 10.1136/bmj.q53 ↗Kurz gefasst
Leserbrief in der Zeitschrift BMJ, online erschienen am 15.01.2024. Verfasst von David Phizackerley. Beteiligte Einrichtung: Drug and Therapeutics Bulletin, London, UK. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Cardiovascular Diseases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 3 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Diabetes Mellitus, Type 2Cardiovascular DiseasesHumansGlucagon-Like PeptidesHypoglycemic AgentsGlucagon-Like Peptide-1 ReceptorSemaglutide
Substanzen
Glucagon-Like PeptidesHypoglycemic AgentsGlucagon-Like Peptide-1 ReceptorSemaglutide
Autor:innen und Institutionen
- Drug and Therapeutics Bulletin, London, UK.
Zitieren
APA
Phizackerley, D. (2024). Semaglutide reduces the absolute risk of major cardiovascular events by 1.5%. BMJ, q53. https://doi.org/10.1136/bmj.q53
Vancouver
Phizackerley D. Semaglutide reduces the absolute risk of major cardiovascular events by 1.5%. BMJ. 2024:q53. doi:10.1136/bmj.q53
BibTeX
@article{Phizackerley2024,
author = {Phizackerley, David},
title = {Semaglutide reduces the absolute risk of major cardiovascular events by 1.5%},
journal = {BMJ},
year = {2024},
pages = {q53},
doi = {10.1136/bmj.q53}
}
EUVIMED